
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dovramilast
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction
Details : Dovramilast is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Erythema Nodosum Leprosum.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 15, 2025
Lead Product(s) : Dovramilast
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Moxidectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Murdoch Childrens Research Institute | Kirby Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Better Options for Lymphatic Filariasis Treatment
Details : Moxidectin is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Elephantiasis, Filarial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 08, 2025
Lead Product(s) : Moxidectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Murdoch Childrens Research Institute | Kirby Institute
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Moxidectin
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Study of Moxidectin in Adults With Scabies
Details : Moxidectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Scabies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2023
Lead Product(s) : Moxidectin
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AMG 634
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Amgen Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Amgen will continue to support the two Phase 2 clinical trials in ENL and TB set to begin in 2021 by providing study drug to both studies and funding the ENL study. This support will help ensure a seamless transition in development to MDGH.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 22, 2020
Lead Product(s) : AMG 634
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Amgen Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Moxidectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Moxidectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Onchocerciasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 17, 2020
Lead Product(s) : Moxidectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Moxidectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Moxidectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Onchocerciasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 23, 2019
Lead Product(s) : Moxidectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Moxidectin
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose-finding Study of Moxidectin for Treatment of Scabies
Details : Moxidectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Scabies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 05, 2019
Lead Product(s) : Moxidectin
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Moxidectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
Details : Moxidectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Onchocerciasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 15, 2019
Lead Product(s) : Moxidectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Moxidectin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers
Details : Moxidectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of QT Effects.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 06, 2017
Lead Product(s) : Moxidectin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Opal-HIV-Gagc
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Phillip T. and Susan M. Ragon Foundation | Imperial College London
Deal Size : Inapplicable
Deal Type : Inapplicable
A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People
Details : Opal-HIV-Gagc is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 14, 2010
Lead Product(s) : Opal-HIV-Gagc
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Phillip T. and Susan M. Ragon Foundation | Imperial College London
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All